Key result
Targeted pharmacological therapies based on the identified mechanism of disease, such as coronary spasm or impaired vasodilatation, can improve symptoms and prognosis in patients with ANOCA.
Why the study?
Evidence from randomized clinical trials for pharmacological therapies targeting specific mechanisms of coronary vasomotor disorders in ANOCA remains sparse.
What are the contemporary pharmacological treatment strategies for patients with ANOCA due to coronary microvascular dysfunction?
Population
Patients with ANOCA due to coronary microvascular dysfunction
Design
Review
Authors
Loading...
May support mechanism-guided therapy in ANOCA; leaves open confirmation by randomized trials before changing practice.
What are the contemporary pharmacological treatment strategies for patients with ANOCA due to coronary microvascular dysfunction?
This review outlines mechanism-targeted pharmacological strategies for managing patients with ANOCA, emphasizing tailored therapy based on invasive diagnostic findings.
McChord et al. (2021) conducted a review in Angina and unobstructed coronary arteries (ANOCA) due to coronary microvascular dysfunction. Targeted pharmacological therapies was evaluated. Targeted pharmacological therapies based on the identified mechanism of disease, such as coronary spasm or impaired vasodilatation, can improve symptoms and prognosis in patients with ANOCA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: